Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies
ACS Medicinal Chemistry Letters April 10, 2025 DOI: 10.1021/acsmedchemlett.5c00182 via OpenAlex
Summary
AI-generated from the abstractPsilocybin reduces phantom and residual limb pain by a clinically meaningful amount. Adaptive sensory environments (ASEs) use biosensors to guide modulation of psychological states during psychoactive therapy. This Patent Highlight reviews pharmacological findings from a psilocybin trial and discusses future integration with ASE systems to improve precision and scalability of psychedelic-assisted interventions.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Psilocybin Adaptive sensory environments |
| Topics | Psilocybin |
| Keywords | Sensory system Phantom limb Imaging phantom Computer science |
| Key finding | Psilocybin reduces phantom and residual limb pain by a clinically meaningful amount. |
Abstract
Psilocybin demonstrates a clinically meaningful reduction in phantom and residual limb pain. Adaptive sensory environments (ASEs) separately offer biosensor-guided modulation of psychological states during psychoactive therapy. This Patent Highlight explores the pharmacological findings of a psilocybin trial and discusses future integration with ASE systems to precision and scale psychedelic-assisted interventions.